# S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

> **NCT00016419** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 130 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT00016419
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2003-07
- **Final completion:** 2007-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016419, "S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00016419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*